Departments of 1 Pharmacodynamics, 2 Clinical Pathology, 3 Cardiosurgery, and 4 Gynaecological Endocrinology, Medical Academy, 15-230 Bialystok, Poland
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Quinolinic acid (QA) is a potent endogenous excitotoxin; elevation of its concentration in an organism has been implicated in the pathogenesis of various disorders. The purpose of this study was the assessment of QA impact on the process of erythropoiesis. Marked increase of QA concentration was observed in plasma and peripheral tissues of uremic rats. These changes were proportional to the amount of the removed renal tissue and positively correlated with the concentration of creatinine but negatively correlated with hematological parameters, i.e., hematocrit and Hb red blood cells count. The changes were accompanied by a slight decrease in the concentration of endogenic erythropoietin (EPO) in the plasma of animals with uremia. Chronic treatment with QA diminished the increase in EPO concentration after introduction of cobalt in rats. These changes were associated with the decrease in all hematological parameters after QA administration. The in vitro study in the conditions of hypoxia showed that QA inhibited the EPO release from HepG2 cells to the culture base. Additionally, in HepG2 cells QA had a dose-dependent inhibitory effect on hypoxia- and cobalt-induced EPO gene expression without any cell toxicity. In conclusion, the erythropoiesis in chronic renal failure could be attributed to the influence of QA on EPO synthesis. Thus we propose that QA can be a uremic toxin responsible for anemia in animals or patients with renal failure.
renal failure
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
ERYTHROPOIESIS DEPENDS ON the proliferative capacity of erythroid progenitor cells in the bone marrow and their stimulation, mainly by erythropoietin (EPO) (2). In chronic renal failure (CRF), the most important trigger of anemia is disturbances in erythropoiesis caused by reduced renal production of EPO as well as resistance of bone marrow cells to this hormone (3).
The literature data and our observations have indicated that in CRF
patients, an increased degradation of tryptophan occurs, accompanied by
a significant increase in the concentration of its plasma metabolites
(18, 19). Quinolinic acid (QA) is the product of
tryptophan oxidation that increases after enzymatic changes in the
kynurenine pathway (Fig. 1)
(21). QA is an endogenous, specific
N-methyl-D-aspartate (NMDA) receptor agonist,
which on activation may direct disturbances in cellular metabolic
processes promoting apoptosis (22). In in vitro
experiments, it has been demonstrated that QA possesses a suppressive
effect on erythroid colony and lymphocyte blast formation
(12). QA is excreted in the urine of healthy subjects, and
it could be accumulated in the blood of uremic patients
(17). Therefore, the increased blood concentration in CRF
may account for uremic symptoms, such as anemia.
|
The present study was undertaken to investigate plasma QA concentrations in rats with chronic renal insufficiency and its influence on EPO production. We provide experimental evidence supporting the hypothesis that the inadequate EPO production in uremic patients might be at least partially attributed to the inhibitory effect of QA on EPO production. We also used the human hepatoma HepG2 cell line, which is a well-characterized in vitro system, to study the mechanisms of EPO production (8). We have demonstrated that these cells release EPO in the culture medium in response to hypoxia or transition metals (cobalt) and that this regulation has been shown to occur at the EPO mRNA level. In addition, we examined the relationship between the QA plasma concentration and the essential hematological and biochemical parameters of healthy rats and animals with experimental renal failure.
![]() |
MATERIALS AND METHODS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Chemicals. The chemicals, which were of analytic reagent grade, were potassium dihydrogen phosphate, phosphoric acid, methanol, hydrochloric acid, and potassium chloride (Merck, Darmstadt, Germany); cobalt chloride hexahydrate, sodium citrate, potassium phosphate, Dulbecco's modified Eagle's medium, penicillin, streptomycin, heat-inactivated fetal bovine serum, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT), isopropanol, Tris(hydroxymethyl)aminomethane hydrochloride, and magnesium chloride (Sigma, St. Louis, MO); QA (ICN); and pentobarbital sodium (Biowed, Pulawy, Poland).
Animals. Inbred adult (2 mo old) male albino rats (Wistar strain) of initial ~180-200 g body wt were used in the experiment. The animals were housed in conventional conditions, at 22 ± 1°C, with a relative humidity of 50 ± 10% and a 12:12-h light-dark cycle. They were allowed free access to drinking water (redistilled water) and rat chow (LSM, total protein 15.9%, dry diet, Fodder Manufactures, Motycz, Poland).
Ethics. Procedures involving the animals and their care conformed to the institutional guidelines, in compliance with national and international laws and Guidelines for the Use of Animals in Biomedical Research (7).
Surgical induction of experimental chronic renal insufficiency in rats. Rats were anesthetized with pentobarbital sodium (40 mg/kg ip). The resection of renal tissue was carried out by using the method described by Ormrod and Miller (16). In sham-operated rats, surgical extraction of the renal capsule was performed. The other experimental groups were as follows. "Moderate" renal insufficiency (CRF1) was induced by the removal of the left kidney, while the right kidney was decorticated in 60%. The rats with "severe" renal failure (CRF2) were subjected to the same surgical procedure as was CRF1, and after 1 wk the additional 20% of the right kidney cortex was removed. The "severe" group of animals was divided into two subgroups, CRF2 and CRF3. The blood and tissues for the biochemical analyses were taken a month after the surgical procedure on CRF2, with the exception of CRF3, in which the biological samples were collected 2 mo after the last surgical intervention.
Effects of QA on erythropoiesis in rats. The erythropoietic effects of sustained intraperitoneal administration of cobalt chloride in a dose of 10 mg/kg daily for 20 days in rats were compared with that in the animals that received the QA in doses of 10 or 100 mg/kg ip for 20 days 6 h before each cobalt injection. Blood was removed for determination of hematological and biochemical parameters at days 0-5, 10, 15, and 20 after treatment.
Blood and tissues sampling.
The animals were anesthetized with pentobarbital sodium (40 mg/kg ip),
and the blood was drawn by heart puncture and put into a tube
containing 3.13% sodium citrate (citrate/blood = 1:9). The plasma
was obtained by blood centrifugation at 3,000 rpm for 15 min (4°C).
After bleeding, rat tissues (kidney, liver, lung, intestine, heart,
spleen, and muscle) were prepared and slices (500 mg) were homogenized
in ice-cold water. Homogenates were additionally sonificated and
centrifuged at 14,000 g for 30 min at 4°C. Samples were
stored at 80°C until assayed.
Determination of QA. QA was measured by using the HPLC technique as described by Werner-Felmayer et al. (26). The chromatographic system (Hewlett-Packard) was composed of an HP 1050 series pump with a Rheodyne injection valve fitted with a sample loop (20 µl). Partisil 10 SAX 250 × 4.6 mm (Phase Separations) column was eluted with 50 mM potassium phosphate (pH 2.0) containing 12% methanol at a flow rate of 2 ml/min. The amount of 2 ml plasma or supernatant of tissue homogenates was concentrated on Sep-Pack cartridges (Waters Accell Plus QMA), washed in 2 ml of water, and eluted with 0.2 ml 4 M H3PO4 (92% recovery of spiked QA). Using an HP 1050 series UV detector, the column effluent was monitored (272 nm). The output of the detector was connected to a single instrument LC-2D ChemStation. Chromatography was carried out at 24°C.
Determination of other biochemical parameters. The following parameters were measured with commercially available kits: creatinine (CRT; Creatinine 30, Cormay), urea (UR; Urea 30, Cormay), and EPO (EPO-Trac I125 RIA Kit, DiaSorin). The biochemical and hematological parameters were measured by the standard methods using an automatic Konelab 4.0.5 and Technikon H1 analyzers. Reticulocytes were stained with methylene blue, and their values [corrected reticulocytes count (CRC)] were adjusted to the degree of anemia (13).
Cell cultures. The HepG2 cell line was obtained from the American Type Culture Collection (HB 8065; tissue: hepatoblastoma, liver; sex: male; age stage: 15 yr; and ethnicity: caucasian). These cells were cultured in Dulbecco's modified Eagle's medium supplemented with penicillin (100 U/ml), streptomycin (100 µg/ml), and 10% heat-inactivated fetal bovine serum in a humidified atmosphere (5% CO2-95% air) at 37°C (Heraeus incubator). Starting from the day before the experiment, 5 × 105 cells/cm2 of confluent cultures were fed with a serum-free medium (24-well polystyrene dishes). At the beginning of the 24-h experimental period, HepG2 cells received fresh medium containing QA (1, 10, 100, and 1,000 µM). In preliminary experiments, we observed that the addition of QA to cultures had no effect on the EPO levels (normoxic conditions) compared with a control group. EPO production by HepG2 was induced by incubation of the cultures with a low (1%) oxygen tension atmosphere or 100 µM of cobalt chloride for 24 h. At the end of the incubation period, supernatants were harvested, clarified by centrifugation, and stored frozen at 80°C until assayed.
Cytotoxicity of QA toward HepG2 cells. QA cytotoxicity (1, 10, 100, and 1,000 µM) was carried out according to Mosmann (15). Exposition time to QA was 24 h. MTT was dissolved in PBS at 5 mg/ml and filtered to sterilize and remove a small amount of insoluble residue present in some batches of MTT. At the times indicated below, stock MTT solution (100 µl/1 ml medium) was added to all wells of the assay and plates were incubated at 37°C for 4 h. Acid-isopropanol (1 ml of 0.04 M HCl in isopropanol) was added to all wells and mixed thoroughly to dissolve the dark blue crystals. After a few minutes at room temperature, the plates were read on a Multiskan EX Labsystems micro-ELISA reader to ensure that all crystals were dissolved, using a test wavelength of 570 nm and a reference wavelength of 630 nm. Plates were normally read within 1 h of adding the isopropanol.
Quantification of EPO mRNA.
We have examined the relative levels of EPO mRNA by using a
semiquantitative RT-PCR procedure. The total RNA was extracted from
HepG2 cells by using TRIzol reagent (Life Technologies, Grand Island,
NY) according to the manufacturer's instructions. RNA was quantified
spectrophotometrically at 260 nm. RNA was then stored in RNase-free
water at 80°C. cDNA synthesis was performed in 50 mM
Tris · HCl (pH 8.3), 75 mM KCl, 3 mM
MgCl2, 10 mM DTT, 1 mM 2-deoxynucleotide 5'-triphosphate
mix, 2.5 µM oligo(dT)15, 20 U RNasin ribonuclease
inhibitor, and 200 U M-MLV RT (Promega, Madison, WI) with 1 µg of
total RNA in a final volume of 20 µl. The mixture was incubated at
42°C for 15 min and then heated to 95°C for 5 min. PCR was
performed in 10 mM Tris · HCl (pH 8.8), 1.5 mM MgCl2, 50 mM KCl, 0.1% Triton X-100, 50 µM
2-deoxynucleotide 5'-triphosphate mix, 200 nM of each primer, 1 unit of DyNAzyme II DNA polymerase (Finnzymes), and 5 µl of
cDNA mixture in a final volume of 25 µl. The expression of the
housekeeping gene,
-actin, was considered as a semiquantitative
control. Sequences of specific primers for PCR were used: sense
5'-ATCACGACGGGCTGTGCTGAACAC-3', positions 335-358, GenBank
accession no. X02157, and antisense 5'-GGGAGATGGCTTCCTTCTGGGCTC-3', positions 623-600, GenBank
accession no. X02157 for EPO (23); and sense
5'-CCAGATCATGTTTGAGACCT-3', positions 913-932, GenBank accession
no. BC009275, and antisense 5'-GCACAGCTTCTCCTTAATGT-3', positions
1204-1185, GenBank accession no. BC009275 for
-actin. PCR was
carried out under the following conditions: 30 s of denaturation
at 94°C, 30 s of annealing at 58°C, and 30 s of extension
at 72°C for 30 cycles, with an additional 5 min of extension for the
last cycle on an MJ Research Thermocycler (model PTC-200, Watertown,
MA). Amplification products were run on a 2% agarose gel. Ethidium
bromide-stained gels were visualized under UV illumination and
photographed, and for each sample the intensity of the signal was
measured with One Dscan/Zero Dscan v2.02 and v1.0 software
(Scanalytics). Ratios of the corresponding peak areas, EPO/
-actin,
were calculated for each sample and used for quantitative calculations
and comparisons.
Statistical analysis. The values are expressed as means ± SE; n represents the number of experiments. Multiple group comparisons were performed by one-way analysis of variance, and significant intergroup differences were assessed by a Tukey-Kramer test. Values of P < 0.05 were regarded as significant. Correlations between plasma concentrations of studied QA and other biochemical or hematological parameters were analyzed by using a Spearman test.
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Effect of experimental renal insufficiency in rats on biochemical
and hematological parameters.
The parameters of renal insufficiency are summarized in Table
1. Rats with moderate, severe 1, and
severe 2 renal failure had significantly increased blood CRT
and UR compared with the control group. At the same time, these changes
were associated with the decrease in hematological parameters, i.e.,
red blood cells count (RBC), Hb, Hct, and CRC. However, mean
corpuscular volume, mean corpuscular Hb, mean corpuscular Hb
concentration, and parameters of iron metabolism, such as serum iron
concentration, transferrin, and total iron-binding capacity, were not
changed.
|
Effect of renal insufficiency on QA plasma and tissue concentration
in rats.
The essential increase in plasma QA concentrations in moderate (CRF1)
and severe 1 and 2 groups (CRF1 and CRF2, respectively) of renal
insufficiency was observed (Fig.
2). At the same time, increases in QA
concentrations in the tissues (kidney, liver, lung, intestine, and
spleen) were observed mainly in CRF2 rats. Additionally, the
relationship between the increase in the plasma QA concentration and
the stage of renal insufficiency was demonstrated. The multiple
regression analysis (Fig. 3) showed that
there was a linear correlation between plasma concentration of CRT and
QA (r = 0.848, P < 0.05) or UR and QA
(r = 0.808, P < 0.05). There was a
significant negative correlation between QA plasma concentrations and
hematological parameters such as RBC (r = 0.841,
P < 0.001), Hb (r =
0.704,
P < 0.001), Hct (r =
0.843,
P < 0.001), and CRC (r =
0.427,
P < 0.023) (Fig. 4).
|
|
|
Effect of chronic QA administration in cobalt chloride-stimulated
erythropoiesis in rats.
After 1 h, administration of QA in 10 and 100 mg/kg ip doses
produced plasma concentrations of 11.2 ± 5.3 and 67.9 ± 16.4 µM, respectively (Fig. 5). The
level of QA in rats then decreased and at 4 h was 0.5 ± 0.1 and 6.3 ± 4.5 µM, respectively. During the next 2 h, the
plasma concentration of QA raised to 0.9 ± 0.1 and 2.2 ± 0.8 µM, respectively.
|
|
Effect of QA on cell viability.
As shown in Fig. 7A, the
viability of HepG2 cells was decreased only at a higher concentration
of QA (1,000 µM). QA in concentrations of 1, 10, and 100 µM had no
effect on this parameter.
|
Effect of QA on medium concentration of EPO. HepG2 cells, when grown in 1% O2 for 24 h, produced approximately five- to sixfold more EPO compared with the cells grown in 21% O2 (Fig. 7B). QA (100 and 1,000 µM) inhibited hypoxia-induced EPO production by 32.1 ± 2.9 and 49.6 ± 2.2% in a dose-dependent manner. However, 24-h exposition to 10 µM of QA had no effect on the EPO production, but 48-h HepG2 exposition significantly decreased the EPO medium concentration by 30.6 ± 4.1%. In normoxic HepG2 cultures, cobalt chloride significantly stimulated EPO production during a 24-h incubation period, but this effect was weaker than under hypoxic conditions. The addition of QA in concentrations of 100 or 1,000 µM inhibited EPO production by 24.9 ± 1.6 and 37.7 ± 2.4%, respectively.
Effect of QA on EPO mRNA induction. In HepG2 cells, hypoxia or cobalt chloride induced EPO gene expression (Fig. 7C). We observed a strong, dose-dependent reduction in EPO gene expression by QA in hypoxic conditions at concentrations ranging from 1 to 100 µM, without any cell toxicity. We observed 35.2 ± 5.4% inhibition of mRNA synthesis with 1 µM of QA, and this concentration is achievable in the plasma of uremic rats. However, this dose of QA had no effect on the induction of EPO mRNA by cobalt chloride. The inhibition of EPO gene expression in these conditions was observed in higher concentrations of QA (100 and 1,000 µM).
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The present study was undertaken to investigate QA concentrations in rats with chronic renal insufficiency and their influence on the EPO production in both in vivo and in vitro experimental conditions. We provide experimental evidence supporting the hypothesis that the inadequate EPO production in uremic patients might be partially attributable to the inhibitory effect of QA on the EPO production.
We used a well-established model of CRF in rats to define mechanisms that may be involved in anemia development, which is observed in kidney failure (16). The course of experimental renal failure was monitored by means of the plasma concentration of CRT and UR, and both of them increased proportionally to the extent of renal tissue resection. In addition, we evaluated basal hematological parameters (Hb, Hct, RBC, and CRC) as the markers of the renal insufficiency progression. We found that they were significantly decreased depending on the stage of the experimental renal insufficiency.
In CRF, a great number of the endogenous metabolites that are normally excreted in urine accumulate in the blood (24). Among these are the products of kynurenate sodium (KYN) degradation (18, 19). We observed a significant increase in the QA concentrations in plasma and peripheral tissues of uremic animals. These changes were proportional to the amount of the removed renal tissue and correlated with the concentration of CRT, a marker of decreased glomerular filtration rate and impaired kidney excretory function. In the CRF2 group, QA plasma concentration was ~10-fold higher than in the control animals. The changes in QA concentration are in accordance with other reports that demonstrated similar patterns in the plasma QA of human patients with CRF. As reported by Saito et al. (20), the increase in serum QA concentrations during uremia is due to the decline in the activity of aminocarboxymuconate-semialdehyde decarboxylase (the enzyme responsible for the degradation of QA to the glutarate pathway). Although serum concentration of QA in CRF was elevated, its renal clearance values were slightly decreased by 20% compared with control subjects. Because urinary excretion of QA also increased, the authors presume that increased solute concentration is not related to a decrease in renal excretion but to an increase in production and decrease in degradation (20).
Our laboratory's earlier study demonstrated that hemodialysis is one of the therapeutic approaches that significantly reduces QA plasma concentration; despite this, QA was still elevated in uremic patients compared with the healthy volunteers (17). Saito et al. (20) found that serum KYN and QA concentrations after hemodialysis were significantly decreased by ~30 and 75%, respectively, compared with prehemodialysis values. The rise in dialysis frequency decreases QA concentration (17) and simultaneously increases erythropoiesis (11).
In our study, the plasma level of QA negatively correlated with hematological parameters.
The predominant reason for insufficient erythropoiesis in renal
diseases is the impossibility of increasing EPO production in response
to the initial anemia (3). The mean values of EPO in CRF
and control rats were not significantly different. The cobalt
administration in rats resulted in a significant increase in EPO plasma
concentration in the control group, and this effect was significantly
weaker in animals with partial ablation of the kidney. Although the
rate of EPO production is clearly related to the degree of anemia and
in turn to the supply of oxygen to the tissues, this relationship is
quite broad, suggesting that a number of other factors play a role.
Among potential agonists are cobalt (4), androgens, and
insulin-derived growth factors (1). It is known that
cobalt may lead to the depression of respiration, oxidative
phosphorylation, and reduced oxygen uptake in kidneys. This metal has
been found to mimic the hypoxia-induced expression of the EPO gene
(4). Antagonists include inflammatory cytokines, such as
tumor necrosis factor, IL-1, and transforming growth factor-
(6). It would seem likely that toxic metabolites retained
in CRF may also impair activation of the EPO gene expression, but
relevant observations are not available.
In the next step of our study, we used an animal model to define mechanisms that may be involved in the observed changes (16). We investigated several parameters of erythropoiesis in healthy rats in response to 20 days of daily exposure to cobalt chloride. The plasma concentration of EPO was significantly increased, and peak concentration was seen after 1-4 days from the start of the experiment. The increase in EPO production results in enhanced red cells formation in bone marrow, which causes the elevation in RBC, Hct, and Hb. This effect was observed after 15 days of cobalt chloride exposure. The chronic administration of QA clearly inhibited the EPO level after cobalt chloride treatment. Additionally, these changes were associated with the decrease in all hematological parameters, i.e., RBC, Hb, and Hct. The concentrations of QA obtained after the lower dose (10 mg/kg) reached the level observed in patients with chronic renal insufficiency (17). QA in a dose of 100 mg/kg caused an increase in the plasma concentration that persisted for 3 h and was much higher that those observed in uremic patients. QA in a dose of 10 mg/kg caused a decrease in the EPO plasma concentration and the inhibition of erythropoiesis, both induced by cobalt chloride. As mentioned above, the resulting concentration is typical for patients with chronic renal insufficiency. Thus we assume that also in vivo QA inhibits erythropoiesis.
We also used the human hepatoma HepG2 cell line, which is a
well-characterized in vitro system, to study mechanisms regulating EPO
production (8). In this experiment, HepG2 cells were grown in 1% O2 or in the presence of cobalt chloride. The
increased EPO production during 24 h in cells grown in 1%
O2 was much stronger compared with cells grown in 21%
O2. These results demonstrated that QA dose dependently
inhibited the production of EPO stimulated by hypoxia or transition
metal (cobalt), without any cell toxicity. The lack of changes in
-actin mRNA and
-fetoprotein levels (data not shown) indicated
that observed activity of QA on EPO production is specific. The
specific effects of QA on EPO synthesis in HepG2 cells suggest that QA
may also be an important regulator of EPO production in vivo. Kynurenic
acid (NMDA receptor antagonist), which acts as an antagonist of QA
(21), did not eliminate the QA effect on EPO production by
HepG2 cells (data not shown), thus the inhibitory activity of QA on EPO
synthesis seems to be not connected with the NMDA receptor. In
addition, the changes observed in EPO synthesis resulted from the
inhibition of the EPO mRNA level. The fact that in these studies the
concentrations of QA used to inhibit hypoxia-induced expression of the
EPO gene in HepG2 cells were within the range of QA in the plasma of
humans (17) or rats (19) with chronic renal
insufficiency suggests that QA could play a role in the anemia observed
in uremia. In our in vitro HepG2 study, we observed that QA in the
concentrations of 1 and 10 µM inhibits EPO gene expression, but we
did not detect any changes in the EPO concentration in the medium. The
first cell reaction after stimulus (in our case QA) is the change in the EPO gene expression, which is followed by the activation of intracellular processes and modulation of EPO synthesis and release. The decrease in the EPO mRNA synthesis does not always reflect the EPO
concentration (in the same interval time). Twenty-four-hour HepG2
exposition to 10 µM of QA (the QA concentrations observed in patients
with chronic renal insufficiency) inhibits the EPO gene expression but
without the decrease in EPO concentration in the medium. In contrast,
48-h HepG2 exposition to 10 µM of QA significantly decreased the EPO
concentration in the medium.
Tissue hypoxia, whether due to altered O2 tension,
O2-carrying capacity, or O2 affinity of the
blood, is the primary stimulus for EPO production (14).
The oxygen sensor is likely to be a heme protein, perhaps a cytochrome
b-like flavo-heme NADPH oxidase that signals by activated oxygen
compounds. H2O2 generated by NADPH oxidase in a
O2-dependent manner is a possible candidate for an
intracellular messenger (5). It is a freely diffusible signaling molecule between the sensor and the transcriptional activator-hypoxia inducible factor (HIF). Hypoxia- or cobalt- induced
expression of the EPO gene depends on the activation of an enhancer
element by HIF. HIF is a heterodimeric nonheme iron protein composed of
- and
-subunits (25). HIF1-
is continually synthesized but rapidly degraded in normoxia.
H2O2 can react with iron in HIF1-
to
generate OH radicals. Hypoxia induces stabilization of the HIF-1
subunit, allowing the formation of the complex HIF1-
-aryl hydrocarbon nuclear translocator protein. The dimerization
induces a conformational change that allows it to bind DNA
(9). Furthermore, there is evidence for a possible role of
the nitric oxide-cGMP system in hypoxic regulation of EPO production
(10). QA may lead to the formation of radical species
(including nitric oxide) that can induce degradation of HIF1-
and,
finally, negatively regulate EPO gene expression. Moreover,
decarboxylation and conversion of QA to nicotinate mononucleotide by
phosphoribosyltransferase is a step in biosynthesis of
NAD+. It is also possible that the concentration of NAD can
influence the redox situation.
In conclusion, this study provides the evidence for the accumulation of QA in the plasma and peripheral tissues in the course of CRF. The erythropoiesis in CRF could be attributed to the influence of QA on EPO synthesis. Thus we proposed that QA could be an uremic toxin responsible for anemia in CRF.
![]() |
ACKNOWLEDGEMENTS |
---|
The authors thank Krzysztof Zolbach for technical assistance.
![]() |
FOOTNOTES |
---|
Address for reprint requests and other correspondence: D. Pawlak, Dept. of Pharmacodynamics, Medical Academy, Mickiewicza 2C, 15-230 Bialystok, Poland (E-mail: dariuszpawlak{at}poczta.onet.pl).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
First published December 3, 2002;10.1152/ajprenal.00327.2002
Received 9 September 2002; accepted in final form 27 November 2002.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1.
Brox, AG,
Zhang F,
Guyda H,
and
Gagnon RF.
Subtherapeutic erythropoietin and insulin-like growth factor-1 correct the anemia of chronic renal failure in the mouse.
Kidney Int
50:
937-943,
1996[ISI][Medline].
2.
Dessypris, EN.
Erythropoiesis.
In: Wintrobe's Clinical Hematology (10th ed.), edited by Pine JW.. Philadelphia, PA: Lippincott Williams & Wilkins, 1999, pt III, sect. 2, chapt. 9, p. 169-176.
3.
Eckardt, KU.
Pathophysiology of renal anemia.
Clin Nephrol
53:
S2-S8,
2000[ISI][Medline].
4.
Fandrey, J,
Frede S,
Ehleben W,
Porwol T,
Acker H,
and
Jelkamann W.
Cobalt chloride and desferrioxamine antagonize the inhibition of erythropoietin production by reactive oxygen species.
Kidney Int
51:
492-496,
1997[ISI][Medline].
5.
Fandrey, J,
Frede S,
and
Jelkmann W.
Role of hydrogen peroxide in hypoxia-induced erythropoietin production.
Biochem J
303:
507-510,
1994[ISI][Medline].
6.
Faquin, WC,
Schneider TJ,
and
Goldberg MA.
Effect of inflammatory cytokines on hypoxia-induced erythropoietin production.
Blood
79:
1987-1994,
1992[Abstract].
7.
Giles, AR.
Guidelines for the use of animals in biomedical research.
Thromb Haemost
58:
1078-1084,
1987[ISI][Medline].
8.
Goldberg, AM,
Glass AG,
Cunningham MJ,
and
Bunn FH.
The regulated expression of erythropoietin by two human hepatoma cell lines.
Proc Natl Acad Sci USA
84:
7972-7976,
1987[Abstract].
9.
Huang, LE,
Arany Z,
Livingston DM,
and
Bunn HF.
Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit.
J Biol Chem
271:
32253-32259,
1996
10.
Huang, LE,
Willmore WG,
and
Gu J.
Inhibition of hypoxia-inducible factor 1 activation by carbon monoxide and nitric oxide.
J Biol Chem
274:
9038-9044,
1999
11.
Ifudu, O.
Evidence that adequacy of dialysis modulates uremic anemia.
Nephron
88:
1-5,
2001[ISI][Medline].
12.
Kawashima, Y,
Sanaka T,
Sugino N,
Takahashi M,
and
Mizoguchi H.
Suppressive effect of quinolinic acid and hippuric acid on bone marrow erythroid growth and lymphocyte blast formation in uremia.
Adv Exp Med Biol
223:
69-72,
1987[Medline].
13.
Koepke, JF,
and
Koepke JA.
Reticulocytes.
Clin Lab Haematol
8:
169-179,
1986[ISI][Medline].
14.
Lacombe, C,
and
Mayeux P.
Biology of erythropoietin.
Haematologica
83:
724-732,
1998[ISI][Medline].
15.
Mosmann, T.
Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.
J Immunol Methods
65:
55-63,
1983[ISI][Medline].
16.
Ormrod, D,
and
Miller T.
Description of a model producing varying degrees of stable uremia.
Nephron
26:
249-254,
1980[ISI][Medline].
17.
Pawlak, D,
Pawlak K,
Malyszko J,
Mysliwiec M,
and
Buczko W.
Accumulation of toxic products degradation of kynurenine in hemodialyzed patients.
Int Urol Nephrol
33:
399-404,
2001[Medline].
18.
Pawlak, D,
Tankiewicz A,
and
Buczko W.
Kynurenine and its metabolites in the rat with experimental renal insufficiency.
J Physiol Pharmacol
52:
755-766,
2001[ISI][Medline].
19.
Pawlak, D,
Tankiewicz A,
Mysliwiec P,
and
Buczko W.
Tryptophan metabolism via kynurenine pathway in experimental chronic renal failure.
Nephron
90:
328-335,
2002[ISI][Medline].
20.
Saito, K,
Fujigaki S,
Heyes MP,
Shibata K,
Takemura M,
Fujii H,
Wada H,
Noma A,
and
Seishima M.
Mechanism of increases in L-kynurenine and quinolinic acid in renal insufficiency.
Am J Physiol Renal Physiol
279:
F565-F572,
2000
21.
Stone, TW.
Neuropharmacology of quinolinic and kynurenic acids.
Pharmacol Rev
45:
309-379,
1993[Abstract].
22.
Stone, TW,
MacGregor DG,
Smith RA,
Jones P,
Behan WM,
and
Graham DI.
Basic mechanisms of kynurenine actions in the central nervous system.
Adv Exp Med Biol
398:
195-201,
1996[Medline].
23.
Stopka, T,
Zivny JH,
Stopkova P,
Prchal JF,
and
Prchal JT.
Human hematopoietic progenitors express erythropoietin.
Blood
91:
3766-3772,
1998
24.
Vanholder, R.
Pathophysiologic effects of uremic retention solutes.
J Am Soc Nephrol
10:
1815-1820,
1999
25.
Wang, GL,
and
Semenza GL.
Purification and characterization of hypoxia-inducible factor 1.
J Biol Chem
270:
1230-1237,
1995
26.
Werner-Felmayer, G,
Werner E,
Fuchs D,
Hausen A,
Reibnegger G,
and
Wachter H.
Characteristics of interferon induced tryptophan metabolism in human cells in vitro.
Biochim Biophys Acta
1012:
140-147,
1989[ISI][Medline].